Vaxxinity Inc Quick Ratio (VAXX) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Vaxxinity Inc   (NASDAQ: VAXX)

Vaxxinity Inc 's Quick Ratio

VAXX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2023, Quick Ratio deteriorated to 1.73 a new company low.

Within Major Pharmaceutical Preparations industry 301 other companies have achieved higher Quick Ratio than Vaxxinity Inc in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 889 to 1285.

Explain Quick Ratio?
How much Cash & cash equivalents VAXX´s has?
What are VAXX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VAXX Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change -47.46 % -33.52 % -18.81 % 8.42 % 24.82 %
Y / Y Cash & cash equivalent Change -64.99 % -57.1 % -50.44 % -45.84 % -40.07 %
Quick Ratio MRQ 1.73 1.97 2.35 2.55 2.59
VAXX's Total Ranking # 1285 # 889 # 805 # 1025 # 948
Seq. Current Liabilities Change -18.35 % -9.33 % -10.15 % -21.02 % 3.32 %
Seq. Cash & cash equivalent Change -28.51 % -23.87 % -17.36 % -22.17 % -12.39 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 302
Healthcare Sector # 548
Overall Market # 1285


Quick Ratio Statistics
High Average Low
5.27 3.15 1.73
(Dec 31 2021)   (Dec 31 2023)




Financial Statements
Vaxxinity Inc 's Current Liabilities $ 18 Millions Visit VAXX's Balance sheet
Vaxxinity Inc 's Cash & cash equivalent $ 30 Millions Visit VAXX's Balance sheet
Source of VAXX's Sales Visit VAXX's Sales by Geography


Cumulative Vaxxinity Inc 's Quick Ratio

VAXX's Quick Ratio for the trailling 12 Months

VAXX Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -25.27 % -6.78 % 4.46 % 22.98 % 60.5 %
Y / Y Cash & cash equivalent TTM Growth -53.63 % -47.5 % -34.42 % -6.15 % 59.52 %
Quick Ratio TTM 2.2 2.4 2.66 3.01 3.54
Total Ranking TTM # 3822 # 3800 # 3791 # 903 # 769
Seq. Current Liabilities TTM Growth -15.1 % -9.36 % -4.53 % 1.72 % 5.9 %
Seq. Cash & cash equivalent TTM Growth -22.33 % -18.29 % -15.52 % -13.51 % -12.06 %

Quick ratio ranking by company, industry and sector >> Back to VAXX Financial Strength Comparisons >> Go to Compare VAXX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in VAXX's Current Liabilities to $17.61 millions, cumulative Quick Ratio to 2.2 below the VAXX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 477 other companies have achieved higher Quick Ratio than Vaxxinity Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 3800 to 3822.

Explain Quick Ratio?
How much Cash & cash equivalents VAXX´s has?
What are VAXX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 478
Healthcare Sector # 963
Within the Market # 3822


trailing twelve months Quick Ratio Statistics
High Average Low
4.21 3.06 2.01
(Sep 30 2022)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Mineralys Therapeutics Inc   4.70 $ 49.304  Millions$ 10.482  Millions
Allakos Inc   4.67 $ 170.794  Millions$ 36.578  Millions
Tempest Therapeutics Inc   4.64 $ 39.230  Millions$ 8.459  Millions
Notable Labs Ltd   4.63 $ 11.825  Millions$ 2.553  Millions
Pyxis Oncology Inc   4.63 $ 119.298  Millions$ 25.759  Millions
Citius Pharmaceuticals Inc   4.59 $ 26.519  Millions$ 5.779  Millions
Scynexis Inc   4.56 $ 74.362  Millions$ 16.303  Millions
Amylyx Pharmaceuticals Inc   4.53 $ 371.362  Millions$ 82.042  Millions
Alumis inc   4.52 $ 48.952  Millions$ 10.819  Millions
Aurinia Pharmaceuticals Inc   4.52 $ 351.900  Millions$ 77.855  Millions
Liquidia Corporation  4.51 $ 83.679  Millions$ 18.550  Millions
Clearside Biomedical Inc   4.48 $ 28.920  Millions$ 6.449  Millions
Novabridge Biosciences  4.48 $ 312.412  Millions$ 69.694  Millions
Summit Therapeutics Inc   4.46 $ 71.461  Millions$ 16.040  Millions
Annovis Bio Inc   4.45 $ 5.755  Millions$ 1.293  Millions
Legend Biotech Corporation  4.43 $ 1,277.700  Millions$ 288.531  Millions
Adial Pharmaceuticals Inc   4.42 $ 2.827  Millions$ 0.640  Millions
Kiniksa Pharmaceuticals International Plc  4.42 $ 206.371  Millions$ 46.727  Millions
Trevena inc   4.37 $ 32.975  Millions$ 7.554  Millions
Galmed Pharmaceuticals Ltd   4.35 $ 13.096  Millions$ 3.009  Millions
Pacira Biosciences inc   4.34 $ 432.312  Millions$ 99.593  Millions
Omeros Corporation  4.31 $ 171.867  Millions$ 39.880  Millions
Metsera Inc   4.29 $ 75.195  Millions$ 17.516  Millions
Amarin Corp Plcuk  4.28 $ 321.184  Millions$ 75.007  Millions
Grace Therapeutics Inc  4.16 $ 17.833  Millions$ 4.282  Millions
Pds Biotechnology Corp  4.15 $ 56.561  Millions$ 13.630  Millions
Monopar Therapeutics Inc   4.13 $ 7.266  Millions$ 1.757  Millions
Arcus Biosciences Inc   4.13 $ 759.000  Millions$ 184.000  Millions
Whitehawk Therapeutics Inc   4.12 $ 108.845  Millions$ 26.395  Millions
Y mabs Therapeutics inc   4.09 $ 78.637  Millions$ 19.226  Millions

Date modified: 2026-09-08T15:11:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.